share_log

HC Wainwright & Co. Maintains Buy on Lisata Therapeutics, Raises Price Target to $15

Benzinga Real-time News ·  Oct 19, 2022 07:02

HC Wainwright & Co. analyst Joseph Pantginis maintains Lisata Therapeutics (NASDAQ:LSTA) with a Buy and raises the price target from $6 to $15.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment